Early prediction of tumor response to treatment: clinical translation of [99MTC]-duramycin

Ended Project Grant Awarded Last action

Award ID
R01CA226531
Recipient
Awarding agency
Obligated
$2,085,038

Award facts

Assistance listing
93.394 Cancer Detection and Diagnosis Research
Completion date
Originally
Place of performance
Pennsylvania, USA

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment -$86,172
Amendment $0
Amendment $40,895
Amendment $460,068
Amendment $514,387
Amendment $0
Amendment $0
Amendment $570,747
Original award $585,113

Quick answers

Who received award R01CA226531?

R01CA226531 was awarded to Molecular Targeting Technologies, Inc. by National Cancer Institute (National Institutes of Health) on January 30, 2019.

How much is award R01CA226531 worth?

$2,085,038 has been obligated on R01CA226531.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award